Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News TCT 2023

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

Caitlin E. Cox

November 03, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

L.A. McKeown

October 27, 2023

Presentation TCT 2023

Optimizing Outcomes With Self-Expanding Valves: The OPTIMIZE PRO Study and Evolut PRO Plus and FX Valves

Presenter: Steven Yakubov

October 25, 2023

Presentation TCT 2023

TCT 248: Assessment of Coronary Cannulation, Commissure and Coronary Alignment post TAVR with the New Supra-Annular, Self-Expanding Evolut FX System

Presenter: Guilherme Attizzani

October 25, 2023

Presentation TCT 2023

TCT 519: Coronary access and percutaneous coronary intervention feasibility after transcatheter aortic valve replacement in failed bioprosthetic valves with ACURATE neo2 versus Evolut PRO+

Presenter: Francesco Giannini

October 25, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

TCT 383: Feasibility of TAV-in-TAV in Evolut valves using in-vivo CT sizing and its impact on coronary obstruction and patient prosthesis mismatch

Presenter: Atsushi Okada

October 24, 2023

Advertisement

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

Optimizing Outcomes With Self-Expanding Valves: The OPTIMIZE PRO Study and Evolut PRO Plus and FX Valves

TCT 248: Assessment of Coronary Cannulation, Commissure and Coronary Alignment post TAVR with the New Supra-Annular, Self-Expanding Evolut FX System

TCT 519: Coronary access and percutaneous coronary intervention feasibility after transcatheter aortic valve replacement in failed bioprosthetic valves with ACURATE neo2 versus Evolut PRO+

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

TCT 383: Feasibility of TAV-in-TAV in Evolut valves using in-vivo CT sizing and its impact on coronary obstruction and patient prosthesis mismatch

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content